ASC-06

N/A

Report date: 2023/06/15 13:57:24
NME

Base Information

Drug NameASC-06
Drug Alias NameALN-VSPALN-VSP01ALN-VSP02ASC-06
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionKinesin-like protein 1 inhibitorsVascular endothelial growth factor A inhibitorsRNA interference
TargetsKinesin-like protein 1Vascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAscletis Pharma IncAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A